Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,090 public trials 2,046 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Completed

LAM Pilot Study With Imatinib Mesylate

NCT03131999

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Columbia University New York, United States
  • Medical University of South Carolina Charleston, South Carolina, United States
View Trial Details
Completed

A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL

NCT02055820

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +6 more
Locations
  • St. Jude Heritage Healthcare Fullerton, California, United States
  • UCLA Jonsson Comprehensive Cancer Center Los Angeles, California, United States
  • Central Coast Medical Oncology Santa Maria, California, United States
  • The West Clinici St Louis, Missouri, United States
View all 52 locations
View Trial Details
Completed

Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

NCT00939770

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +22 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Children's Hospital of Orange County Orange, California, United States
  • UCSF Medical Center-Parnassus San Francisco, California, United States
View all 28 locations
View Trial Details
Completed

Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

NCT01742286

Conditions
ALK-activated Tumors, Granuloma, Granuloma, Plasma Cell, +26 more
Locations
  • Dana Farber Cancer Institute Dept of Onc Boston, Massachusetts, United States
  • Memorial Sloan Kettering SC - 7 New York, United States
  • Cincinnati Children s Hospital Medical Center Dept of Oncology Cincinnati, Ohio, United States
  • St Jude s Childrens Research Hospital Dept of Oncology Memphis, Tennessee, United States
View all 23 locations
View Trial Details
Completed

Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma

NCT00903968

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Cape Cod Hospital Hyannis, Massachusetts, United States
  • Milford Hospital Milford, Massachusetts, United States
  • Newton-Wellesley Hospital Newton, Massachusetts, United States
View Trial Details

Related conditions